Key Points – Autolus Therapeutics said first-quarter 2026 product revenue rose to $26.2 million, driven by early traction for AUCATZYL in the U.S. and U.K., and it reaffirmed full-year revenue guidance of $120 million to $135 million. – The company reported a positive gross…
rgin for the quarter and expects manufacturing efficiency gains to support further improvement, targeting a 65% to 70% gross profit margin in its peak adult ALL business. – Autolus ended the quarter with GBP 229.4 million in cash and investments and said its current resources, including anticipated AUCATZYL revenue, should fund operations into the fourth quarter of 2027. Autolus Therapeutics (NASDAQ:AUTL) reported higher first-quarter 2026 product revenue and said its commercial launch of AUCATZYL is gaining traction in the U.S. and U.K., while reiterating full-year revenue guidance for the cell therapy
Chief Executive Officer Dr. Christian Itin said the company had a “very good first quarter,” with $26.2 million in revenue booked. He said Autolus is seeing “nice traction building” in the U.S. and in the early stages of its U.K. launch, where more than 10 centers are already active under the NHS access program.
Autolus maintained its 2026 guidance for AUCATZYL net product revenue of $120 million to $135 million, including contributions from the U.S. and U.K. markets. Itin said the company has about 73 U.S. centers active and expects to increase that number beyond 80 by the end of the year. Gross Margin Turns Positive Chief Financial Officer Rob Dolski said total net product revenue for the first quarter was $26.2 million, compared with $9 million in the first quarter of 2025.